Multimorbidity, Polypharmacy, Severe Hypoglycemia, and Glycemic Control in Patients Using Glucose-Lowering Drugs for Type 2 Diabetes: A Retrospective Cohort Study Using Health Insurance Claims in Japan.

Diabetes Ther · 2023 · PMC10241751 · PMID 37195511

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Our data showed that DPP4i was the most widely prescribed glucose-lowering drug among patients taking monotherapy, which reflected a strong trend toward DPP4i prescription reported in Japan [ 31 , 32 ], whereas European and US guidelines at the time of this study recommended the use of metformin along with first-line treatment [ 33 , 34 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.